SCHEMBL22159079

SCHEMBL22159079

CC(N)c1ccc(Nc2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.57
HSD17B10 Q99714 6/20 0.57
CYP3A4 P08684 5/20 0.57
ALOX12 P18054 4/20 0.57
TSHR P16473 4/20 0.57
TDP1 Q9NUW8 4/20 0.57
L3MBTL1 Q9Y468 3/20 0.57
ALOX15 P16050 3/20 0.57
LMNA P02545 2/20 0.57
THRB P10828 1/20 0.57
RECQL P46063 1/20 0.57
ATM Q13315 1/20 0.57
MAPK1 P28482 2/20 0.56
PTGS1 P23219 1/20 0.56
SLC6A2 P23975 1/20 0.56
PTGS2 P35354 1/20 0.56
HTR2B P41595 1/20 0.56
MAPT P10636 5/20 0.52
HPGD P15428 3/20 0.52
HTT P42858 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diphenylamine SCHEMBL29088504 0.84 HSD17B10 (0.67) ALDH1A1HSD17B10CYP3A4ALOX12TSHR
SCHEMBL28318549 0.83 ALDH1A1 (0.52) ALDH1A1HSD17B10CYP3A4ALOX12TSHR
SCHEMBL2749867 0.82 ALDH1A1 (0.62) ALDH1A1HSD17B10CYP3A4ALOX12TSHR
SCHEMBL4547310 0.80 ALDH1A1 (0.59) ALDH1A1HSD17B10CYP3A4ALOX12TSHR
Diphenylamine SCHEMBL28251400 0.79 HSD17B10 (0.60) ALDH1A1HSD17B10CYP3A4ALOX12TSHR
SCHEMBL29142718 0.79 SMN1; SMN2 (0.61) ALDH1A1HSD17B10TSHRMAPTMEN1
SCHEMBL2431450 0.78 ALDH1A1 (0.69) ALDH1A1HSD17B10CYP3A4ALOX12TSHR
SCHEMBL24932018 0.78 DPP4 (0.58) ALDH1A1LMNASLC6A2HIF1AADRB2
SCHEMBL42393 0.78
SCHEMBL830 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020141439-A1 HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) 2020-07-09 WO disclosed
US-20200206233-A1 HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) 2020-07-02 US disclosed
US-20200206233-A1 HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) 2020-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200206233-A1 HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS IDH1, IDH2, IDH3A ALDH1A1 149/4885HSD17B10 108/4885CYP3A4 1010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.